GSK PLC's (LSE:GSK, NYSE:GSK) respiratory syncytial virus vaccine, Arexvy, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use to extend its use to adults aged 50-59 who are at increased risk of RSV.
If approved, it will be the first RSV vaccine for this age group in the EU. The final decision is expected by September. This jab is already approved in Europe for adults aged 60 and over.
RSV is a common virus that can cause serious respiratory issues, especially in people with conditions like COPD, asthma, and diabetes. Each year, RSV leads to significant hospitalisations and deaths among older adults.
GSK's treatment has been approved by the US Food & Drug Administration for adults aged 50-59 at increased risk.